Skip to main content
. 2020 Nov 7;26(41):6455–6474. doi: 10.3748/wjg.v26.i41.6455

Figure 2.

Figure 2

Impact of key model variables on the cost-effectiveness of infliximab maintenance therapy relative to conventional maintenance therapy for moderate to severe Crohn’s disease in one-way sensitivity analyses. CD: Crohn’s disease; CMT: Conventional maintenance therapy; ICER: Incremental cost-effectiveness ratio; IMT: Infliximab maintenance therapy.